Eribulin Induction of Immunogenic Cell Death (ICD): Comparison With Other Cytotoxic Agents and Temporal Relationship of ICD Biomarkers
Anticancer Research · 2025
DOI: 10.21873/anticanres.17391 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Anticancer Research, 2025. Verfasst von Mingfa Zang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Crown Bioscience Inc., Taicang, P.R. China. Hauptthemen laut MEDLINE: Ketones, Furans, Antineoplastic Agents, Immunogenic Cell Death. Die Arbeit wurde bisher 5-mal zitiert (Crossref).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Crown Bioscience Inc., Taicang, P.R. China.
- IQ Proteomics, Framingham, MA, U.S.A.
- Eisai Inc., Cambridge, MA, U.S.A. bruce_littlefield@eisai.com.
Zitieren
APA
Zang, M., Zheng, J., An, X., Li, B. O., Yang, H., Erickson, B., Kunz, R., & Littlefield, B. A. (2025). Eribulin Induction of Immunogenic Cell Death (ICD): Comparison With Other Cytotoxic Agents and Temporal Relationship of ICD Biomarkers. Anticancer Research. https://doi.org/10.21873/anticanres.17391
Vancouver
Zang M, Zheng J, An X, Li BO, Yang H, Erickson B, et al. Eribulin Induction of Immunogenic Cell Death (ICD): Comparison With Other Cytotoxic Agents and Temporal Relationship of ICD Biomarkers. Anticancer Research. 2025. doi:10.21873/anticanres.17391
BibTeX
@article{Zang2025,
author = {Zang, Mingfa and Zheng, Jia and An, Xiaoyu and Li, B O and Yang, Huajun and Erickson, Brian and Kunz, Ryan and Littlefield, Bruce A},
title = {Eribulin Induction of Immunogenic Cell Death (ICD): Comparison With Other Cytotoxic Agents and Temporal Relationship of ICD Biomarkers},
journal = {Anticancer Research},
year = {2025},
doi = {10.21873/anticanres.17391}
}
EUVIMED